- Isopyrazam sets new standard in disease control
- Consistent crop yield enhancement
- Product registrations across multiple crops planned
Syngenta today announced that it has received European Union (EU) approval for isopyrazam, the first active ingredient from its strong pipeline of next generation fungicides. Approval represents a major step forward in the control of a wide spectrum of damaging fungal diseases, including best-in-class performance against Yellow Rust.
Isopyrazam’s advanced “double-binding” technology ensures strong adhesion to fungus and to leaf wax, providing long-lasting and durable disease protection.
Under the EU’s provisional approval system, British and Irish cereal farmers have for the past two growing seasons experienced the benefits of isopyrazam, which is marketed as SEGURIS™ in wheat and BONTIMA™ in barley. These growers have consistently achieved better disease control, which has helped deliver higher crop yields: SEGURIS treatments increase yield by up to two tonnes per hectare versus current chemistries.
John Atkin, Chief Operating Officer, said: “Breakthrough chemical innovation is an enduring part of our integrated strategy. Isopyrazam sets the highest standards for disease control and yield response and this approval means growers throughout the EU can now benefit from this important addition to our portfolio.”
Syngenta intends to register a range of products containing isopyrazam in major EU markets for use on cereals and others crops such as oilseed rape, vegetables and pome fruits.
Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.